FR

About IHU Prism

Prism is a translational and medical research program launched in March 2020.

» After proving the effectiveness of precision medicine through pioneering clinical trials, we could not stop there and only offer targeted treatments to patients who had relapsed from conventional therapies. This is the whole ambition of the PRISM project: to guide patients who need it towards targeted therapies and early trials as soon as the diagnosis is made. They will thus have access to innovations while the cure of the disease is still possible. «

Prof. Fabrice André, Director of Prism

Prism IHU is a precision medicine programme that aims to obtain a better understanding of the biology of each patient’s cancer to reduce mortality.

The goal is to identify patients with aggressive forms of cancer as soon as they are diagnosed and characterise the biology of the disease, in order to offer patients the most suitable treatment from the very start.

Prism IHU wants to develop an integrative translational research approach, using innovative methodology and tools: artificial intelligence, epigenetics, clonal tumour heterogeneity using circulating DNA analysis and spatial biology. This exhaustive molecular profiling should lead to the creation of a digital map summarising the biology of each patient, hopefully making it possible to identify new biomarkers and treatment response predictors (drug sensitivity, toxicity).

A unique partnership

Prism was founded by four leading research and education organisations.

Gustave Roussy, a private non-profit organization, is one of the leading cacner center in the world. It was ranked as the 3rd best cancer center worldwide by Newsweek Magazine in 2022.

Inserm (Institut National de la Recherche Médicale) is the leading research organization for basic and translational cancer research in France.

University Paris-Saclay is the largest French university, 16th in Shanghai ranking in 2021, 1st worldwide in mathematics.

CentraleSupélec is a graduate engineering school and research institution located within the University Paris-Saclay campus.

Unicancer is a national federation of 18 cancer centres. It entered the Prism consortium as member in 2021.

Gustave Roussy Foundation and ARC Foundation are also members.